Evidence map›Paper›PMID 40976899›Full record

ReviewCurrent pharmaceutical design2026

Promising Targets and Drugs for Improving Head and Neck Cancer Response to Radiotherapy.

Faris Anad Muhammad, Ayat Hussein Adhab, Morug Salih Mahdi, Ashishkumar Kyada, Subbulakshmi Ganesan, Deepak Bhanot, K Satyam Naidu, Aseel Salah Mansoor, Usama Kadem Radi, Nasr Saadoun Abd and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Faris Anad MuhammadCollege of Pharmacy, Alnoor University, Nineveh, Iraq.
Ayat Hussein AdhabDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Morug Salih MahdiCollege of MLT, Ahl Al Bayt University, Karbala, Iraq.
Ashishkumar KyadaMarwadi University Research Center, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, 360003, Gujarat, India.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Deepak BhanotCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
K Satyam NaiduDepartment of Chemistry, Raghu Engineering College, Visakhapatnam, Andhra Pradesh, 531162, India.
Aseel Salah MansoorGilgamesh Ahliya University, Baghdad, Iraq.
Usama Kadem RadiCollege of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, Iraq.
Nasr Saadoun AbdMedical Technical College, Al-Farahidi University, Baghdad, Iraq.
Munther KadhimCollege of Pharmacy, The Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck cancers, particularly Head and Neck Squamous Cell Carcinoma (HNSCC), encompass a diverse group of malignancies with intricate cellular landscapes. The Tumor Microenvironment (TME) is characterized by constant communication between cancer cells and their surrounding cells. Stromal components, immune infiltrates, and Extracellular Matrix (ECM) elements all play crucial roles in this process. These dialogues shape tumor behavior, spread, and treatment resistance. At the molecular level, DNA Damage Response (DDR) by tumoral cells can reduce cell elimination via Ionizing Radiation (IR). Human Papillomavirus (HPV) infection, in some cases, further complicates the picture. Recent findings highlight how these molecular responses, as well as immune modulation, remodeling cell metabolism, enhanced growth factors, and hypoxia in TME, can influence tumor responses to IR. These findings may lead to strategies for radiosensitizing head and neck cancers. Unraveling these interactions is key to developing more effective treatments. This review focuses on different mechanisms of radioresistance in head and neck cancers. Then, we provide an overview of different targets and potential adjuvants or drugs for radiosensitization of these malignancies.

Indexed as

Antineoplastic AgentsHead and Neck NeoplasmsRadiation-Sensitizing AgentsHumansTumor MicroenvironmentAntineoplastic AgentsRadiation-Sensitizing AgentsHead and neck cancerimmunotherapyradiosensitizationradiotherapytargeted therapytumor microenvironment

Identifiers

PMID40976899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.